AMAG Pharmaceuticals Inc. (NASDAQ:AMAG) traded up 2.9% during trading on Thursday . The company traded as high as $25.69 and last traded at $25.37, with a volume of 834,194 shares traded. The stock had previously closed at $24.66.

A number of brokerages have recently issued reports on AMAG. Zacks Investment Research cut shares of AMAG Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, April 29th. Leerink Swann restated an “outperform” rating on shares of AMAG Pharmaceuticals in a research report on Saturday, April 16th. Jefferies Group restated a “buy” rating on shares of AMAG Pharmaceuticals in a research report on Thursday, June 2nd. Raymond James Financial Inc. cut shares of AMAG Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Wednesday, May 4th. Finally, Ladenburg Thalmann cut shares of AMAG Pharmaceuticals from a “buy” rating to a “neutral” rating in a research report on Monday, March 28th. Seven investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $38.20.

The company has a market capitalization of $871.02 million and a price-to-earnings ratio of 84.25. The stock has a 50-day moving average price of $22.56 and a 200-day moving average price of $23.72.

AMAG Pharmaceuticals (NASDAQ:AMAG) last posted its quarterly earnings results on Tuesday, May 3rd. The specialty pharmaceutical company reported $0.94 EPS for the quarter, missing the consensus estimate of $1.11 by $0.17. During the same period in the previous year, the business earned $1.17 EPS. The business had revenue of $117.60 million for the quarter, compared to the consensus estimate of $124.83 million. The firm’s quarterly revenue was up 41.9% compared to the same quarter last year. Equities analysts expect that AMAG Pharmaceuticals Inc. will post $5.20 EPS for the current year.

Other hedge funds have added to or reduced their stakes in the company. Rhumbline Advisers increased its stake in AMAG Pharmaceuticals by 10.1% in the fourth quarter. Rhumbline Advisers now owns 37,447 shares of the specialty pharmaceutical company’s stock valued at $1,131,000 after buying an additional 3,420 shares during the period. BNP Paribas Arbitrage SA increased its position in shares of AMAG Pharmaceuticals by 6.6% in the fourth quarter. BNP Paribas Arbitrage SA now owns 62,716 shares of the specialty pharmaceutical company’s stock worth $1,893,000 after buying an additional 3,903 shares during the last quarter. Dimensional Fund Advisors LP increased its position in shares of AMAG Pharmaceuticals by 2.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 397,816 shares of the specialty pharmaceutical company’s stock worth $12,010,000 after buying an additional 8,435 shares during the last quarter. Principal Financial Group Inc. increased its position in shares of AMAG Pharmaceuticals by 69.2% in the fourth quarter. Principal Financial Group Inc. now owns 34,282 shares of the specialty pharmaceutical company’s stock worth $1,034,000 after buying an additional 14,017 shares during the last quarter. Finally, LSV Asset Management increased its position in shares of AMAG Pharmaceuticals by 19.9% in the fourth quarter. LSV Asset Management now owns 93,842 shares of the specialty pharmaceutical company’s stock worth $2,833,000 after buying an additional 15,600 shares during the last quarter.

AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.